You are here:

alendronate colecalciferol (Fosavance)

Advice

Following an abbreviated submission

Alendronate/colecalciferol (Fosavance) is accepted for use within NHS Scotland for the treatment of postmenopausal osteoporosis in patients at risk of vitamin D insufficiency who require treatment with both alendronate and vitamin D and for whom once-weekly administration is appropriate. The combination preparation is cost saving compared to the two drugs administered separately.

Weekly administration of vitamin D represents a departure from routine clinical practice. In patients who also require calcium supplementation this will have to be administered separately, using a calcium preparation that does not also contain vitamin D.

Drug Details

Drug Name: alendronate colecalciferol (Fosavance)
SMC Drug ID: 213/05
Manufacturer: MSD
Indication: Postmenopausal osteoporosis
BNF Category:
Sub Category: 6.6 Drugs affecting bone metabolism
Submission Type: Abbreviated Submission
Status: Superseded
Date Advice Published: 7 November 2005

Back